The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional ...
Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, ...
Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, ...
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients ...
Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...
The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation ...
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback